Donnerstag, 4. April | 11:00 - 12:30 Uhr | Basic Science Box
Freie Vortragssitzungen
New Therapeutic Targets in Myocardial Infarction
Vorsitz/Chair: Christian Kupatt (München), Kai C. Wollert (Hannover)
Agenda
11:00
(V670)
New insights into thyroid hormone (TH) action in ischemic heart disease
S. Dörr (Dortmund)
11:07
Discussion
11:11
(V671)
Inhibition of the NLRP3 Inflammasome enhances engraftment of transplanted cells and augments cardiac function in a murine infarction model
E. Carls (Bonn)
11:18
Discussion
11:22
(V672)
MicroRNA-100 protects against ischemia-reperfusion injury
F. Pankratz (Freiburg im Breisgau)
11:29
Discussion
11:33
(V673)
Neu therapy for delaying post-ischaemic heart failure development: Angiotensin II receptor 2 agonist Vasoconstriction-Inhibiting Factor (VIF) improves post-ischaemic left ventricular function in mice
L. Hua (Aachen)
11:40
Discussion
11:44
(V674)
Everolimus modulates the immune response in the myocardium after acute myocardial infarction and prevents LV-dilatation
M. Kaldirim (Düsseldorf)
11:51
Discussion
11:55
(V675)
Targeting of the sheddase ADAM9 improves cardiac function after myocardial infarction
J. Marks (Dresden)
12:02
Discussion
12:06
Targeting cardiac fibrosis after myocardial infarction
J. Haag (Heidelberg), S. Hayat (Aachen), N. Frey (Heidelberg), J. Krijgsveld (Heidelberg), F. Leuschner (Heidelberg), T. Kuhn (Heidelberg)
12:13
Discussion
12:17
(V677)
Impact of downregulating the transcription factor Sox9 in epicardial cells or fibroblasts after myocardial infarction
J. Eresch (Mannheim)
12:24
Discussion